11
May

08:00 AM PDT

Oncology

Strategy Meeting West Coast USA 2022

The premier meeting for all West Coast USA Oncology professionals

The Westin St. Francis San Francisco on Union Square

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Oncology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.

Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Oncology professionals from across the West Coast, in San Francisco, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

See the agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Oncology strategy meeting.

Susan Weidner

Senior Vice President IntrinsiQ Analytics

Susan Weidner joined IntrinsiQ Specialty Solutions in 2013.  As the Senior Vice President, Susan is responsible for the Analytics business unit along with our community-based research network, AdvanceIQ Network, and our precision medicine strategies.  In her position, she also coordinates activities across both our software and analytics businesses in support of our specialty distribution and physician group purchasing organizations.
With over 20 years of healthcare experience, she has led the design, development and implementation of innovative healthcare solutions, including those driven by healthcare informatics.  Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers and provider organizations in demonstrating the value of their product(s) and/or organizations.
Prior to joining IntrinsiQ Specialty Solutions, Susan held executive leadership positions at pharmaceutical, healthcare consulting, and precision medicine companies.

Claudia Hesselmann, PhD

Co-founder & CEO ARENSIA

Tatiana Eidus

Director, Corporate Development North America Arensia

Mike Reed, PhD

Chief Scientist, PhysioPD Rosa & Co.

Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client biopharmaceutical and consumer product organizations.
At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and have led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide.
Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes.
Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.

Dan Norton

Associate Director, Product Management Personalis

Roman Hrynchuk

Chief Operating Officer Sanaclis

Gajanan Bhat

Senior Vice President, Development Team Lead TORL Biotherapeutics, LLC

Kun Chen

Senior Directio, Biostatistics, Oncology Gilead Sciences

Sashka Dimitrievska

Global Therapeutic Area Head Oncology Clinical Insights AstraZeneca

Ken Kobayashi

Senior Vice President Kinnate Biopharma

Anthony Maida

Chief Clinical Officer – Translational Medicine Oncotelic Therapeutics, Inc.

Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease.  Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer.  He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc.  Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc.  Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.  Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities.  Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development.  Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.  Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees.  Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology.  He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society.  Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Mike Mattie

Director, Translational Sciences and External Collaborations Kite Pharma

John Rossi

Vice President Translational Medicine Cargo Therapeutics

Oscar Segurado

Chief Medical Officer ASC Therapeutics

Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.

Angus Sinclair

Vice President Oncology IGM Biosciences

Lixia Wang

Senior Vice President, Data Science & Informatics Atreca, Inc

David Zarling

Chief Executive Officer Colby Pharmaceuticals

Sanjay Khare

Senior Vice President Coherus BioSciences

First name	Last name	Job title	Company name	Photo URL	Bio Position
Susan	Weidner	Senior Vice President	IntrinsiQ Analytics	https://proventainternational.com/wp-content/uploads/2021/09/Susan-Weidner.jpg	Susan Weidner joined IntrinsiQ Specialty Solutions in 2013. As the Senior Vice President, Susan is responsible for the Analytics business unit along with our community-based research network, AdvanceIQ Network, and our precision medicine strategies. In her position, she also coordinates activities across both our software and analytics businesses in support of our specialty distribution and physician group purchasing organizations. With over 20 years of healthcare experience, she has led the design, development and implementation of innovative healthcare solutions, including those driven by healthcare informatics. Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers and provider organizations in demonstrating the value of their product(s) and/or organizations. Prior to joining IntrinsiQ Specialty Solutions, Susan held executive leadership positions at pharmaceutical, healthcare consulting, and precision medicine companies.
Claudia	Hesselmann, PhD	Co-founder & CEO	ARENSIA	https://proventainternational.com/wp-content/uploads/2020/01/Claudia-Hesselmann-Arensia-Headshot-e1584469734743.png	Claudia Hesselmann, PhD, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.
Tatiana	Eidus	Director, Corporate Development North America	Arensia	https://proventainternational.com/wp-content/uploads/2020/05/Tatiana-Eidus.jpg	Tatiana Eidus received her Master’s Degree in Biophysics from Moscow State University. Entering the industry more than a decade ago, Tatiana has accumulated wide expertise in all the operational aspects of initiating and managing Phase I-III trials across Europe and US. Prior to joining ARENSIA Exploratory Medicine, Tatiana worked for GSK and Merck. Primarily focused on early-stage exploratory programs, she conducted trials in various disease areas. In her current role as Director Corporate Development, Tatiana supports ARENSIA’s partners in the US, supervising cross-functional coordination throughout study planning, start-up and execution.
Mike	Reed, PhD	Chief Scientist, PhysioPD	Rosa & Co.	https://proventainternational.com/wp-content/uploads/2021/01/Mike-Reed-New.jpg	Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client biopharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and have led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide. Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes. Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.
Dan	Norton	Associate Director, Product Management	Personalis	https://proventainternational.com/wp-content/uploads/2022/04/Dan-Norton.jpg
Roman	Hrynchuk	Chief Operating Officer	Sanaclis	https://proventainternational.com/wp-content/uploads/2021/02/Roman-Hrynchuk-New.jpg	Roman leads key company business by providing strategic direction and day-to-day oversight. With 15 years of experience in pharmaceutical business, Roman leverages a profound and deep knowledge of clinical research and a passion for operations, to continuously improve the company’s performance, whilst retaining compliance with regulatory requirements and best practices. Additionally, Roman is responsible for the regular control and management of SanaClis’s operational departments such as, Clinical Operations, Clinical Trial Supply Chain, Data Management, Pharmacovigilance/Medical Affairs and Sourcing. Further to Roman’s oversight of the aforementioned internal departments within SanaClis, Roman also plays a vital role in ensuring the implementation and continuous development of key operational strategies/objectives and thereby accomplishing the company’s high standards and corporate goals.
Gajanan	Bhat	Senior Vice President, Development Team Lead	TORL Biotherapeutics, LLC	https://proventainternational.com/wp-content/uploads/2021/04/Gajanan-Bhat.jpg
Kun	Chen	Senior Directio, Biostatistics, Oncology	Gilead Sciences	https://proventainternational.com/wp-content/uploads/2021/09/Kun-2-e1631533400801.jpg
Sashka	Dimitrievska	Global Therapeutic Area Head Oncology Clinical Insights	AstraZeneca	https://proventainternational.com/wp-content/uploads/2021/02/Sashka-Dimitrievska.jpeg	Sashka leads the Global AstraZeneca Oncology Information Practice (IP) department focused on generating informed decisions in late stage drug development across the oncology portfolio. Prior to joining AstraZeneca in 2017, Sashka worked in Alexion Pharmaceuticals Strategy & Intelligence, followed by a role in Alexion US Marketing. She holds a PhD in Biomedical Engineering and an MBA training from Yale University.
Ken	Kobayashi	Senior Vice President	Kinnate Biopharma	https://proventainternational.com/wp-content/uploads/2021/09/ken-kobayashi.jpeg
Anthony	Maida	Chief Clinical Officer – Translational Medicine	Oncotelic Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2022/02/Anthony-Maida-1.jpg	Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease. Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer. Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities. Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc. Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees. Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.
Mike	Mattie	Director, Translational Sciences and External Collaborations	Kite Pharma	https://proventainternational.com/wp-content/uploads/2022/02/Mike-Mattie.jpg
John	Rossi	Vice President Translational Medicine	Cargo Therapeutics	https://proventainternational.com/wp-content/uploads/2021/09/johnrossi.jpg
Oscar	Segurado	Chief Medical Officer	ASC Therapeutics	https://proventainternational.com/wp-content/uploads/2021/09/Photo_Oscar-Segurado_F0-e1631533577811.jpeg	Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.
Angus	Sinclair	Vice President Oncology	IGM Biosciences	https://proventainternational.com/wp-content/uploads/2021/01/Angus-Sinclair-scaled.jpg
Lixia	Wang	Senior Vice President, Data Science & Informatics	Atreca, Inc	https://proventainternational.com/wp-content/uploads/2020/01/Lixia-Wang.jpg
David	Zarling	Chief Executive Officer	Colby Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/09/David-Zarling.jpg	David Alan Zarling, MA Ph.D. MBA is a Co-Founder and CEO of Colby Pharmaceutical Company and leads teams in clinical development of Intra-Nasal, -Lymphatic, -Venous Diagnostics, and companion Immune Modulating anti-viral and anti-cancer immunotherapeutics. David successfully managed Colby teams in asset sales of anti-inflammatory and anti-cancer drugs and in Colby’s subsequent merger acquisition of Othera Pharmaceuticals’ anti-viral, anti-inflammatory, anti-cancer clinical small molecule pharmaceutical drug portfolios. David also successfully completed the worldwide exclusive license from MannKind Corporation to their entire portfolio of infectious, neoplastic, autoimmune, and allergic disease immuno-therapeutic and -diagnostic clinical products.
Sanjay	Khare	Senior Vice President	Coherus BioSciences	https://proventainternational.com/wp-content/uploads/2022/04/Sanjay-Khare.jpg

Susan Weidner, Claudia Hesselmann, PhD, Tatiana Eidus, Mike Reed, PhD, Dan Norton, Roman Hrynchuk, Gajanan Bhat, Kun Chen, Sashka Dimitrievska, Ken Kobayashi, Anthony Maida, Mike Mattie, John Rossi, Oscar Segurado, Angus Sinclair, Lixia Wang, David Zarling, Sanjay Khare

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D San Francisco

Oncology

Strategy Meeting West Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >The Westin St. Francis San Francisco on Union Square

Fresh Oncology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Become an official strategy meeting partner

Press play to hear what your colleagues had to say…

See the agenda and facilitator line-up

Meet Our 2022 Facilitators

Susan Weidner

Claudia Hesselmann, PhD

Tatiana Eidus

Mike Reed, PhD

Dan Norton

Roman Hrynchuk

Gajanan Bhat

Kun Chen

Sashka Dimitrievska

Ken Kobayashi

Anthony Maida

Mike Mattie

John Rossi

Oscar Segurado

Angus Sinclair

Lixia Wang

David Zarling

Sanjay Khare

Our 2022 Thought Leader

Our 2022 Co-Hosts

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

The Westin St. Francis San Francisco on Union Square